Citigroup Inc. started coverage on shares of Myovant Sciences Ltd (NASDAQ:MYOV) in a report published on Monday morning. The firm issued a buy rating and a $17.00 price objective on the stock.
Several other equities analysts have also commented on MYOV. JMP Securities began coverage on shares of Myovant Sciences in a research report on Monday. They issued an outperform rating and a $23.00 price objective for the company. Barclays PLC began coverage on shares of Myovant Sciences in a research report on Monday. They issued an overweight rating and a $18.00 price objective for the company. Finally, Robert W. Baird began coverage on shares of Myovant Sciences in a research report on Monday. They issued an outperform rating and a $20.00 price objective for the company. Five research analysts have rated the stock with a buy rating, The company currently has an average rating of Buy and an average price target of $19.50.
Myovant Sciences (NASDAQ:MYOV) opened at 11.91 on Monday. The company’s market capitalization is $519.16 million. The firm has a 50 day moving average of $11.43 and a 200-day moving average of $11.43. Myovant Sciences has a 52-week low of $10.26 and a 52-week high of $13.31.
Myovant Sciences Company Profile
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Receive News & Ratings for Myovant Sciences Ltd Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Myovant Sciences Ltd and related companies with MarketBeat.com’s FREE daily email newsletter.